Editas Medicine, Inc. (EDIT)

Trade EDIT now with
1/9/2023 8:22:08 AM Editas Medicine To Reduce Headcount By About 20%
11/17/2022 7:24:52 AM Editas Medicine Announces Clinical Data Demonstrating Proof Of Concept Of EDIT-101 From Phase 1/2 BRILLIANCE Trial
12/20/2021 7:06:56 AM Editas Medicine: FDA Clears IND Application For EDIT-301 For Transfusion-Dependent Beta Thalassemia
6/28/2021 10:05:13 AM Editas Medicine Gains 10%
2/8/2021 8:07:12 AM Editas Medicine Appoints James Mullen As CEO
1/20/2021 10:56:26 PM Editas Medicine Prices Public Offering Of 3.5 Mln Shares At $66/Shr
1/11/2021 6:11:09 AM Editas Medicine Says Chief Scientific Officer Charles Albright Is Stepping Down On January 15
1/11/2021 6:09:16 AM Editas Says FDA Cleared Initiation Of Safety Phase Of EDIT-301 Clinical Trial